Business Description
NGM Biopharmaceuticals Inc
NAICS : 325414
SIC : 2836
Compare
Compare
Traded in other countries / regions
0IK.Germany
•
NGM.USA
Description
NGM Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics based on scientific understanding of key biological pathways for the treatment of cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's products include NGM282 (aldafermin), NGM313 (MK-3655), NGM120, NGM120, NGM621, and NGM395, all these are focused on NASH, diabetes, oncology, AMD and metabolic disease.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 44.88 | |||||
| Equity-to-Asset | 0.85 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 2.83 | |||||
| Beneish M-Score | -2.66 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -15.5 | |||||
| 3-Year EPS without NRI Growth Rate | -438.3 | |||||
| 3-Year FCF Growth Rate | -67.5 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 63.9 | |||||
| 9-Day RSI | 51.75 | |||||
| 14-Day RSI | 43.68 | |||||
| 6-1 Month Momentum % | -62.53 | |||||
| 12-1 Month Momentum % | -72.76 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.5 | |||||
| Quick Ratio | 6.5 | |||||
| Cash Ratio | 6.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.3 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -267.03 | |||||
| Net Margin % | -264.09 | |||||
| ROE % | -48.6 | |||||
| ROA % | -41.45 | |||||
| ROIC % | -355.63 | |||||
| ROC (Joel Greenblatt) % | -1270.75 | |||||
| ROCE % | -48.6 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 7.55 | |||||
| PB Ratio | 1.6 | |||||
| Price-to-Tangible-Book | 1.6 | |||||
| EV-to-EBIT | -1.05 | |||||
| EV-to-EBITDA | -1.09 | |||||
| EV-to-Revenue | 2.81 | |||||
| EV-to-FCF | -1.22 | |||||
| Price-to-Net-Current-Asset-Value | 1.72 | |||||
| Price-to-Net-Cash | 1.83 | |||||
| Earnings Yield (Greenblatt) % | -95.24 |
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NGM
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 58.111 | ||
| EPS (TTM) ($) | -1.95 | ||
| Beta | 1.27 | ||
| Volatility % | 64.65 | ||
| 14-Day RSI | 43.68 | ||
| 14-Day ATR ($) | 0.46604 | ||
| 20-Day SMA ($) | 5.48 | ||
| 12-1 Month Momentum % | -72.76 | ||
| 52-Week Range ($) | 2.92 - 19.14 | ||
| Shares Outstanding (Mil) | 81.73 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NGM Biopharmaceuticals Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
NGM Biopharmaceuticals Inc Analysis
Share your researchHeadlines
See More
No news.